Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Lin XiaoKlaartje SomersJayne E MurrayRuby PandherMawar KarsaEmma RoncaAngelika BongersRachael L TerryAnahid EhtedaLaura D GambleNatalia IssaevaKaterina I LeonovaAisling O'ConnorChelsea MayohPooja VenkatHazel Q Y QuekJennifer BrandFrances K KusumaJessica A PettittErin MosmannAdam KearnsGeorgina EdenStephanie AlfredSophie AllanLei ZhaiAlvin KamiliAndrew J GiffordDaniel R CarterMichelle J HendersonJamie I FletcherGlenn MarshallRicky W JohnstoneAnthony J CesareDavid S ZieglerAndrei V GudkovKaterina V GurovaMurray D NorrisMichelle HaberPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The combination of CBL0137 and panobinostat is effective and well-tolerated in preclinical models of aggressive high-risk neuroblastoma, warranting further preclinical and clinical investigation in other pediatric cancers. On the basis of its potential to boost IFN and immune responses in cancer models, the drug combination holds promising potential for addition to immunotherapies.